{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:53:01Z","timestamp":1791874381446,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.dld.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T12:36:23Z","timestamp":1714826183000},"page":"1425-1432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations"],"prefix":"10.1016","volume":"56","author":[{"given":"Ferdinando","family":"D'Amico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lusetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10080","key":"10.1016\/j.dld.2024.04.012_bib0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.dld.2024.04.012_bib0002","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dld.2024.04.012_bib0003","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.04.012_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/5354320","article-title":"Factors influencing disability and quality of life during treatment: a cross-sectional study on IBD patients","volume":"2019","author":"Marinelli","year":"2019","journal-title":"Gastroenterol Res Pract"},{"issue":"10","key":"10.1016\/j.dld.2024.04.012_bib0005","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.dld.2024.04.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.01.017","article-title":"Positioning therapies in ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2024.04.012_bib0007","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640620977405","article-title":"Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study","volume":"9","author":"Festa","year":"2021","journal-title":"UEG Journal"},{"issue":"9","key":"10.1016\/j.dld.2024.04.012_bib0008","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/17474124.2020.1772057","article-title":"Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach","volume":"14","author":"D'Amico","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.04.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17745029","article-title":"Inflammatory bowel disease: towards a personalized medicine","volume":"11","author":"Flamant","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"10.1016\/j.dld.2024.04.012_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrgastro.2016.128","article-title":"Current best practice for disease activity assessment in IBD","volume":"13","author":"Walsh","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2024.04.012_bib0011","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohn's Colitis"},{"issue":"7","key":"10.1016\/j.dld.2024.04.012_bib0013","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohn's Colitis"},{"issue":"5","key":"10.1016\/j.dld.2024.04.012_bib0014","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10611860902839502","article-title":"Colonic treatments and targets: issues and opportunities","volume":"17","author":"McConnell","year":"2009","journal-title":"J Drug Target"},{"issue":"27","key":"10.1016\/j.dld.2024.04.012_bib0015","first-page":"3204","article-title":"Current treatment of ulcerative colitis","volume":"17","author":"Meier","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.dld.2024.04.012_bib0016","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/0016-5085(90)90329-Y","article-title":"Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid","volume":"98","author":"Ahnfelt-R\u00f8nne","year":"1990","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2024.04.012_bib0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/ecp.12.2","article-title":"Mesalamine in the treatment and maintenance of remission of ulcerative colitis","volume":"5","author":"Ham","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dld.2024.04.012_bib0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4292\/wjgpt.v6.i4.137","article-title":"Mesalazine preparations for the treatment of ulcerative colitis: are all created equal?","volume":"6","author":"Ye","year":"2015","journal-title":"WJGPT"},{"issue":"3","key":"10.1016\/j.dld.2024.04.012_bib0019","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2024.04.012_bib0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.dld.2024.04.012_bib0021","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2036.2008.03751.x","article-title":"Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis - methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa","volume":"28","author":"Lichtenstein","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis: systematic review: pharmacokinetics of oral 5asa for ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.04.012_bib0023","article-title":"Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis?","volume":"1","author":"Feagan","year":"2013","journal-title":"Evid Cochrane Rev: Inflammat Bowel Dis"},{"issue":"8","key":"10.1016\/j.dld.2024.04.012_bib0024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1208\/s12249-021-02133-4","article-title":"Budding multi-matrix technology\u2014a retrospective approach, deep insights, and future perspectives","volume":"22","author":"Sriram","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"10.1016\/j.dld.2024.04.012_bib0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/1756283X17709974","article-title":"MMX \u00ae technology and its applications in gastrointestinal diseases","volume":"10","author":"Nardelli","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.dld.2024.04.012_bib0026","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.MIB.0000158386.25660.1e","article-title":"A New Oral Delivery System for 5-ASA: preliminary Clinical Findings for MMX","volume":"11","author":"Prantera","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.04.012_bib0027","unstructured":"https-::farmaci.agenziafarmaco.gov.it:aifa:servlet:PdfDownloadServlet?pdfFileName=footer_000051_037734_RCP.pdf&sys=m0b1l3.pdf."},{"issue":"3","key":"10.1016\/j.dld.2024.04.012_bib0028","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/17474124.2.3.299","article-title":"Mesalamine with MMX\u2122 technology for the treatment of ulcerative colitis","volume":"2","author":"Schreiber","year":"2008","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2024.04.012_bib0029","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1365-2036.2006.03082.x","article-title":"Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study","volume":"24","author":"D'Haens","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2006.10.025","article-title":"Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis","volume":"5","author":"Lichtenstein","year":"2007","journal-title":"Clinical Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0031","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","article-title":"Once-daily, high-concentration MMX mesalamine in active ulcerative colitis","volume":"132","author":"Kamm","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.20580","article-title":"Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis","volume":"15","author":"Kamm","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.dld.2024.04.012_bib0033","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gut.2007.138248","article-title":"Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis","volume":"57","author":"Kamm","year":"2008","journal-title":"GutGut"},{"issue":"26","key":"10.1016\/j.dld.2024.04.012_bib0034","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.04.012_bib0035","article-title":"A review of multimatrix system (MMX) mesalazine in the management of ulcerative colitis","volume":"1","author":"Hawthorne","year":"2009","journal-title":"Clin Med Ther"},{"issue":"3","key":"10.1016\/j.dld.2024.04.012_bib0036","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.gtc.2010.08.011","article-title":"Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel Disease","volume":"39","author":"Sonu","year":"2010","journal-title":"Gastroenterol. Clin. North Am."},{"issue":"4","key":"10.1016\/j.dld.2024.04.012_bib0037","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/BF02849976","article-title":"Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system","volume":"24","author":"Tenjarla","year":"2007","journal-title":"Adv Therapy"},{"issue":"9","key":"10.1016\/j.dld.2024.04.012_bib0038","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1046\/j.1365-2036.2003.01564.x","article-title":"Gastrointestinal transit and release of 5-aminosalicylic acid from 153 Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers: GASTROINTESTINAL TRANSIT OF MESALAZINE","volume":"17","author":"Brunner","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.dld.2024.04.012_bib0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2015.02.051","article-title":"Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations","volume":"484","author":"Goyanes","year":"2015","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.dld.2024.04.012_bib0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/acs.molpharmaceut.6b00641","article-title":"Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract","volume":"14","author":"Yu","year":"2017","journal-title":"Mol. Pharmaceutics"},{"issue":"2","key":"10.1016\/j.dld.2024.04.012_bib0041","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2036.2007.03361.x","article-title":"MMX Multi Matrix System \u00ae mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials","volume":"26","author":"Sandborn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dld.2024.04.012_bib0042","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2024.04.012_bib0043","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.14309\/00000434-201410002-01740","article-title":"Long-term pooled safety analysis of once-daily multimatrix mesalamine: 1740","volume":"109","author":"Sanchez","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.dld.2024.04.012_bib0044","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2036.2006.02809.x","article-title":"Systematic review: adherence issues in the treatment of ulcerative colitis","volume":"23","author":"Kane","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.dld.2024.04.012_bib0046","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2036.2003.01648.x","article-title":"Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease: COMPLIANCE WITH MAINTENANCE THERAPY IN IBD","volume":"18","author":"Shale","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.dld.2024.04.012_bib0047","series-title":"Cochrane database of systematic reviews","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","author":"Feagan","year":"2012"},{"key":"10.1016\/j.dld.2024.04.012_bib0048","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","author":"Wang","year":"2016","journal-title":"Cochrane Database Systemat Rev"},{"issue":"8","key":"10.1016\/j.dld.2024.04.012_bib0049","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"2020","author":"Murray","year":"2020","journal-title":"Cochrane Database Systemat Rev"},{"issue":"6","key":"10.1016\/j.dld.2024.04.012_bib0050","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2036.2010.04575.x","article-title":"Randomised clinical trial: delayed-release oral mesalazine 4.8g\/day vs. 2.4g\/day in endoscopic mucosal healing - ASCEND I and II combined analysis: randomised clinical trial: mucosal healing with delayed-release mesalazine","volume":"33","author":"Lichtenstein","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2024.04.012_bib0051","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.069","article-title":"Delayed-release oral mesalamine 4.8g\/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.dld.2024.04.012_bib0052","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00384-019-03271-9","article-title":"Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system","volume":"34","author":"Ballester","year":"2019","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0053","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-230X-12-132","article-title":"Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis","volume":"12","author":"Mitra","year":"2012","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2024.04.012_bib0054","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2036.2008.03865.x","article-title":"Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares","volume":"29","author":"Higgins","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dld.2024.04.012_bib0055","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5217\/ir.2018.00033","article-title":"Medication non-adherence in inflammatory bowel diseases is associated with disability","volume":"16","author":"Perry","year":"2018","journal-title":"Intest Res"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0056","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000530139","article-title":"Medication formulation preference of mild and moderate ulcerative colitis patients: a European survey","volume":"8","author":"H\u00e9buterne","year":"2023","journal-title":"Inflamm Intest Dis"},{"key":"10.1016\/j.dld.2024.04.012_bib0058","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/PPA.S127039","article-title":"Adherence in ulcerative colitis: an overview","volume":"11","author":"Testa","year":"2017","journal-title":"PPA"},{"issue":"9","key":"10.1016\/j.dld.2024.04.012_bib0059","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/ibd.23024","article-title":"Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41687-018-0046-5","article-title":"Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study","volume":"2","author":"Willian","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"10.1016\/j.dld.2024.04.012_bib0061","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX \u00ae with Asacol \u00ae","volume":"30","author":"Prantera","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dld.2024.04.012_bib0062","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ajg.2012.103","article-title":"Once-Daily MMX\u00ae mesalamine for endoscopic maintenance of remission of ulcerative colitis","volume":"107","author":"D'Haens","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.dld.2024.04.012_bib0067","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/03007995.2022.2081453","article-title":"Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes","volume":"38","author":"Pandey","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"Supplement_1","key":"10.1016\/j.dld.2024.04.012_bib0068","doi-asserted-by":"crossref","first-page":"i110","DOI":"10.1093\/ecco-jcc\/jjac190.0083","article-title":"DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients","volume":"17","author":"Dignass","year":"2023","journal-title":"J Crohn's Colitis"},{"issue":"5","key":"10.1016\/j.dld.2024.04.012_bib0065","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apt.17622","article-title":"Review article: translating STRIDE-II into clinical reality \u2013 Opportunities and challenges","volume":"58","author":"Dignass","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dld.2024.04.012_bib0066","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.dld.2024.04.012_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clinical Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.dld.2024.04.012_bib0070","doi-asserted-by":"crossref","first-page":"i090","DOI":"10.1093\/ecco-jcc\/jjab232.080","article-title":"DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45mg once daily followed by maintenance upadacitinib 15 or 30mg once daily in patients with moderately to severely active Ulcerative Colitis","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohn's Colitis"},{"issue":"3","key":"10.1016\/j.dld.2024.04.012_bib0071","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cgh.2022.08.024","article-title":"Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease","volume":"21","author":"Mahmoud","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2024.04.012_bib0073","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000502886","article-title":"Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding","volume":"101","author":"Restellini","year":"2020","journal-title":"DigestionDigestion"},{"issue":"1","key":"10.1016\/j.dld.2024.04.012_bib0074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2024.04.012_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102232","article-title":"Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study","volume":"65","author":"Croft","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.dld.2024.04.012_bib0076","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3390\/jcm12052005","article-title":"Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists","volume":"12","author":"Nardone","year":"2023","journal-title":"J Clin Med"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T01:05:44Z","timestamp":1725411944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824007138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1590865824007138"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.012","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}